My Portfolio
+
LINK YOUR PORTFOLIO

Mustang Bio Inc MBIO:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 6:14 PM EDT
0.76quote price arrow up+0.0186 (+2.5088%)
Volume
1,419
Close
0.7414quote price arrow down-0.0201 (-2.6395%)
Volume
69,685
52 week range
0.53 - 7.00
Loading...
  • Open0.7562
  • Day High0.8048
  • Day Low0.7413
  • Prev Close0.7615
  • 52 Week High7.00
  • 52 Week High Date07/07/25
  • 52 Week Low0.53
  • 52 Week Low Date02/05/26

Latest On Mustang Bio Inc

Key Stats

  • Market Cap5.618M
  • Shares Out7.58M
  • 10 Day Average Volume0.06M
  • Dividend-
  • Dividend Yield-
  • Beta2.06

Latest On Mustang Bio Inc

KEY STATS

  • Open0.7562
  • Day High0.8048
  • Day Low0.7413
  • Prev Close0.7615
  • 52 Week High7.00
  • 52 Week High Date07/07/25
  • 52 Week Low0.53
  • 52 Week Low Date02/05/26
  • Market Cap5.618M
  • Shares Out7.58M
  • 10 Day Average Volume0.06M
  • Dividend-
  • Dividend Yield-
  • Beta2.06

RATIOS/PROFITABILITY

  • EPS (TTM)-0.49
  • P/E (TTM)-1.51
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-5.737M
  • ROE (TTM)-44.62%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-68,986.00%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/12/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and autoimmune diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. It is developing a...
Michael Weiss J.D.
Executive Chairman of the Board
Manuel Litchman M.D.
President, Chief Executive Officer, Interim Chief Financial Officer, Director
Address
95 Sawyer Rd, Suite 110
Waltham, MA
02453
United States